Fludarabine exposure in patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy
This research study is looking at how a chemotherapy drug called Fludarabine acts in the body. This drug is given to patients before they receive a newer type of cancer treatment called CAR-T cell therapy. CAR-T cell therapy is used for certain blood cancers. The main goal is to measure how much Fludarabine stays in the body and for how long. Researchers also want to see how quickly the body gets rid of the drug. This information will help doctors understand the drug better, which could lead to more effective and safer treatments for people with blood cancer receiving CAR-T cell therapy. The study includes adult patients of all sexes who are already undergoing this treatment.
At a glance
What is this study about?
This study is designed to understand how a chemotherapy drug called Fludarabine works in your body. Fludarabine is an important part of getting ready for a special type of cancer treatment called CAR-T cell therapy. Before you receive CAR-T cells, doctors often give you some chemotherapy, including Fludarabine, to prepare your body. This preparation is called 'lymphodepletion' and it helps the CAR-T cells work better against the cancer.
The main aim of this study is to measure exactly how much Fludarabine is in your blood and for how long it stays there after you've been given the treatment. We will also look at the highest level it reaches in your blood. By understanding these details, doctors can learn more about how Fludarabine affects different people ahead of CAR-T therapy. This knowledge is important because it could help doctors give the right dose of Fludarabine to each patient, making the treatment as effective and safe as possible for people with blood cancers.
Researchers will also collect information like your age, sex, weight, and how well your kidneys are working. This additional information helps us understand if any of these personal factors affect how your body handles Fludarabine. The study is a 'Phase IV' study, which means it's looking at a treatment that is already in use, to gather more detailed information about its effects in a real-world setting.
Key takeaways
- This study helps understand how a cancer drug (Fludarabine) works in the body.
- It's for adults getting ready for CAR-T cell therapy for blood cancer.
- The main goal is to measure drug levels in your blood.
- Participation involves extra blood tests during your planned treatment.
- It aims to improve future cancer treatments for others.
- Your medical care is not affected by joining or leaving the study.
Who may be eligible?
This study is looking for adults aged 18 or older. It is open to both men and women.
You would be considered for this study if you are already scheduled to receive a specific type of chemotherapy called Fludarabine. This Fludarabine treatment must be given to prepare you for CAR-T cell therapy. CAR-T cell therapy is a treatment for certain blood cancers.
Essentially, if you are an adult patient undergoing Fludarabine-based chemotherapy in preparation for CAR-T cell therapy for a blood cancer, you would likely be eligible to take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you scheduled to receive Fludarabine chemotherapy?
- Is this Fludarabine treatment to prepare you for CAR-T cell therapy?
- Are you being treated for a blood cancer?
What does participation involve?
If you take part in this study, it's important to know that you'll be receiving the standard Fludarabine treatment you would normally get before your CAR-T cell therapy. The main difference is that the research team will take extra blood samples at specific times during and after your Fludarabine treatment. These blood samples will help them measure the levels of Fludarabine in your body.
You won't have any extra hospital visits just for the study, as the blood samples will be taken during your already planned hospital stays for your cancer treatment. There are no additional medicines given specifically for this study. The total duration of your involvement in the study will depend on how long it takes to collect the necessary blood samples after you complete your Fludarabine treatment. This study basically adds extra monitoring to your existing treatment plan.
Potential risks and benefits
Locations (1)
- —UnverifiedBelgium
Common questions
What is CAR-T cell therapy?
It's a special type of cancer treatment where some of your immune cells are taken, changed in a lab to fight cancer better, and then put back into your body.
What is Fludarabine for?
Fludarabine is a chemotherapy drug given to prepare your body before CAR-T cell therapy. It helps the new immune cells work more effectively.
Will I get different treatment than planned?
No, you will receive the same Fludarabine treatment you were already scheduled for. The study just involves extra monitoring.
How does this study help me?
While this study won't change your direct treatment, the information collected will help doctors understand the drug better, potentially leading to improved treatments for future patients.
Do I have to take part?
No, taking part is completely your choice. You can say no or leave the study at any time without it affecting your medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.